AGM
CRVS icon

Alpine Global Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Alpine Global Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-11,641
Closed -$62.3K – 152
2024
Q4 		$62.3K Buy
+11,641
New +$86.9K 0.02% 144

Other funds holding CRVS

OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Samlyn Capital
Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $643M AUM 343.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Alpine Global Management's CRVS Position: Q1 2025 in Review

Alpine Global Management sold out of Corvus Pharmaceuticals (CRVS) in Q1 2025, closing a stake of 11,641 shares — an estimated $62.3K sold.

Alpine Global Management first reported a position in CRVS in Q4 2024 and held it in 1 quarter. The position peaked at $62.3K in Q4 2024. 88 funds tracked by Wall St. Rank hold CRVS as of Q1 2025.

  • Alpine Global Management reported no remaining Corvus Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Alpine Global Management sold 11,641 Corvus Pharmaceuticals shares in Q1 2025, an estimated $62.3K.
  • Alpine Global Management first reported a position in Corvus Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Alpine Global Management's Corvus Pharmaceuticals position peaked at $62.3K in Q4 2024.
  • 88 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2025.

Based on Alpine Global Management's 13F filing for Q1 2025, filed 15 May 2025.